Dechra launches Laverdia, the first FDA-approved oral treatment for canine lymphoma

Dechra said it is now shipping Laverdia (verdinexor) tablets, which the company described as "the first oral treatment for canine lymphoma approved by the U.S. Food and Drug Administration."

According to Dechra, "the prescription medication is designed for at-home administration and demonstrates efficacy against B-cell and T-cell lymphoma." The company said "the targeted therapy works by slowing disease progression while generally sparing healthy cells."

The 80% figure and what it reveals

Dechra reported that an estimated 80% of dogs diagnosed with lymphoma do not receive traditional intravenous chemotherapy. The oral format addresses that gap by giving general practitioners a treatment option they can initiate immediately after diagnosis, whether owners are considering further options, waiting to begin multi-agent chemotherapy protocols, or opting for a less aggressive approach.

The company positioned Laverdia as a primary care alternative for a disease that has historically required referral to oncology for IV protocols. Laura Olsen, Dechra's North American president and chief marketing officer, said the drug "combines FDA-approved treatment, at-home administration, and dedicated professional support" to help care teams and pet owners act sooner.

What this changes for the general practitioner

For the associate DVM, Laverdia means you can now offer lymphoma treatment in-house instead of referring out. You keep the case, you build oncology experience without IV chemotherapy training, and you have a concrete option when a client declines referral on cost or logistics. The drug's targeted mechanism, sparing healthy cells while slowing disease progression, may also reduce the side-effect conversations that kill compliance before treatment starts.

For the owner-DVM, this is a new revenue stream for a common diagnosis you used to send to specialists. Case retention improves when clients were declining referral, and you can initiate treatment the day of diagnosis rather than losing the client to inaction or to a competitor who stocks the drug. The flexibility Dechra described, starting treatment while owners consider next steps, also means you can keep the conversation open rather than closing it with a referral slip.

We write one of these every week for people who make clinical and business decisions in practice. Subscribe to VeterinaryPracticeNow.

Our read on the approval

The FDA approval matters because it moves lymphoma treatment from specialist-only to general practice, and it does so with an oral format that removes the IV barrier. The 80% untreated figure Dechra cited represents a large pool of diagnosed dogs whose owners said no to the referral or the IV protocol, and Laverdia gives you a way to say yes to treatment anyway.

What we do not know yet: pricing, insurance coverage, and whether the drug becomes standard of care or a niche option for clients who decline referral. Dechra said the company provides dedicated professional support, but we have no detail on what that support includes or how it is accessed. The efficacy claim, "demonstrates efficacy against B-cell and T-cell lymphoma," is general. We would want to see the study data, sample size, and response rates before we could compare it to multi-agent chemotherapy protocols.

The approval is real, the format is new, and the 80% untreated figure is the market Dechra is addressing. Whether this becomes the first-line option or the fallback when referral fails depends on the data we have not seen yet and the price point Dechra has not disclosed.

← Back to the Newsdesk